Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ, Espejo Valle-Inclan J, Hami N, Lõhmussaar K, Kopper O, Vreuls CPH, Jonges GN, van Diest P, Nguyen L, Clevers H, Kloosterman WP, Cuppen E, Snippert HJG, Zweemer RP, Witteveen PO, Stelloo E.
Cell Rep. 2020 Jun 16;31(11):107762. doi: 10.1016/j.celrep.2020.107762.
The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups.
Gat I, Shlush E, Quach K, Librach CL.
Syst Biol Reprod Med. 2015;61(6):336-44. doi: 10.3109/19396368.2015.1089607. Epub 2015 Oct 30.
The normal menstrual cycle in women.
Mihm M, Gangooly S, Muttukrishna S.
Anim Reprod Sci. 2011 Apr;124(3-4):229-36. doi: 10.1016/j.anireprosci.2010.08.030. Epub 2010 Sep 3.
Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
Ahn B, Moon D, Kim HS, Lee C, Cho NH, Choi HK, Kim D, Lee JY, Nam EJ, Won D, An HJ, Kwon SY, Shin SJ, Jung HR, Kwon D, Park H, Kim M, Cha YJ, Park H, Lee Y, Noh S, Lee YM, Choi SE, Kim JM, Sung SH, Park E.
Nat Commun. 2024 May 18;15(1):4253. doi: 10.1038/s41467-024-48667-6.
Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.
Cavarzerani E, Caligiuri I, Bartoletti M, Corona G, Perin T, Palumbo A, Ditto A, Occhiali T, Canzonieri V, Rizzolio F.
J Adv Res. 2025 Aug 7:S2090-1232(25)00598-3. doi: 10.1016/j.jare.2025.08.009. Online ahead of print.
Pathological response of ovarian cancer to neoadjuvant chemotherapy.
Ivantsov AO.
Chin Clin Oncol. 2018 Dec;7(6):59. doi: 10.21037/cco.2018.09.07.
Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine.
Cappuccio S, Distefano MG, Ghizzoni V, Fagotti A, Scambia G.
Gynecol Oncol Rep. 2020 Feb 13;32:100547. doi: 10.1016/j.gore.2020.100547. eCollection 2020 May.
New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.
Torkildsen CF, Austdal M, Jarmund AH, Kleinmanns K, Lamark EK, Nilsen EB, Stefansson I, Sande RK, Iversen AC, Thomsen LCV, Bjørge L.
Front Immunol. 2024 Jun 14;15:1394497. doi: 10.3389/fimmu.2024.1394497. eCollection 2024.
The best ovarian reserve marker to predict ovarian response following controlled ovarian hyperstimulation: a systematic review and meta-analysis.
Salemi F, Jambarsang S, Kheirkhah A, Salehi-Abargouei A, Ahmadnia Z, Hosseini HA, Lotfi M, Amer S.
Syst Rev. 2024 Dec 18;13(1):303. doi: 10.1186/s13643-024-02684-0.
A nuclear polymorphism at the 8q24 region is associated with improved survival time and chemo-response in high-grade serous ovarian cancer.
Ikoma D, Cardillo N, Devor E, Gonzalez-Bosquet J.
Oncol Lett. 2021 Oct;22(4):733. doi: 10.3892/ol.2021.12994. Epub 2021 Aug 11.
